Beam Therapeutics (BEAM) Change in Accured Expenses (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Change in Accured Expenses data on file, last reported at -$16.3 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$16.3 million, up 11.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.9 million (up 119.06% YoY), and the FY2025 annual result was $7.7 million, up 113.32% from the prior year.
• Change in Accured Expenses retreated to -$16.3 million in Q1 2026 per BEAM's latest filing, from $14.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $70.4 million in Q4 2023 and troughed at -$24.3 million in Q1 2024.
• A 5-year average of $38411.8 and a median of -$266000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses soared 733.84% in 2023, then sank 7225.56% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $8.4 million in 2022, then soared by 733.84% to $70.4 million in 2023, then plunged by 105.79% to -$4.1 million in 2024, then jumped by 450.87% to $14.3 million in 2025, then tumbled by 213.71% to -$16.3 million in 2026.
• Business Quant data shows BEAM's Change in Accured Expenses at -$16.3 million in Q1 2026, $14.3 million in Q4 2025, and $2.0 million in Q3 2025.